XENETIC BIOSCIENCES, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
XENETIC BIOSCIENCES, INC. (XBIO) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 29.00 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-03-12
- XENETIC BIOSCIENCES, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 29.00K shares, a 866.67% increase from fiscal 2024.
- XENETIC BIOSCIENCES, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 3.00K shares, a 40.00% decline from fiscal 2023.
- XENETIC BIOSCIENCES, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 5.00K shares, a 0.00% change from fiscal 2022.
- XENETIC BIOSCIENCES, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 5.00K shares, a 99.00% decline from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 0 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|
| 2025-12-31 | 29.00K shares 10-K · filed 2026-03-12 | |||
| 2024-12-31 | 3.00K shares 10-K · filed 2026-03-12 | |||
| 2023-12-31 | 5.00K shares 10-K · filed 2025-03-18 | |||
| 2022-12-31 | 5.00K shares 10-K · filed 2024-03-21 | 100.00K shares 10-K · filed 2023-03-22 | ||
| 2021-12-31 | 500.00K shares 10-K · filed 2023-03-22 | |||
| 2020-12-31 | 400.00K shares 10-K · filed 2022-03-22 | 391.00K shares 10-K · filed 2021-03-16 | ||
| 2019-12-31 | 516.00K shares 10-K · filed 2021-03-16 | |||
| 2018-12-31 | 65.00K shares 10-K · filed 2020-03-26 | 800.00K shares 10-K · filed 2019-03-29 | ||
| 2017-12-31 | 600.00K shares 10-K · filed 2019-03-29 | |||
| 2016-12-31 | 1.70M shares 10-K · filed 2018-03-30 | |||
| 2015-12-31 | 360.00K shares 10-K · filed 2017-03-31 | 12.03M shares 10-K · filed 2016-03-30 | ||
| 2014-12-31 | 11.87M shares 10-K · filed 2016-03-30 | |||
| 2014-09-30 | 23.07M shares 10-Q · filed 2014-11-14 | |||
| 2014-06-30 | 22.96M shares 10-Q · filed 2014-08-14 | |||
| 2014-03-31 | 22.81M shares 10-Q · filed 2014-05-20 | |||
| 2013-09-30 | 26.51M shares 10-Q · filed 2014-11-14 | |||
| 2013-06-30 | 25.44M shares 10-Q · filed 2014-08-14 | |||
| 2013-03-31 | 25.24M shares 10-Q · filed 2014-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |